IgGenix sprints to clinic with peanut allergy candidate and additional $40M

A small, Eli Lilly-backed biotech has received $40 million on its way to the clinic with a self-administered injection for peanut allergies.

IgGenix unveiled a Series B round on Monday to support what CEO Jessica Grossman calls a “revolutionary” approach to preventing both food and non-food allergies, from dairy to dust to dogs.